TUESDAY, Nov. 9 (HealthDay News) -- The more
isoflavone-containing soy products a young woman eats, the lower
her odds for developing invasive breast cancers, according to
research slated to be presented at a meeting of the American
Association of Cancer Research in Philadelphia.
That was among the good news, but other research at the meeting
found that hormone replacement therapy might raise women's odds for
The soy study looked specifically at isoflavones, organic
compounds found in certain foods. These compounds contain
antioxidants that are thought to be protective against breast
The study included 683 women with breast cancer and 611 women
without the disease. It found that participants who consumed the
most isoflavones had a 30 percent lower risk of developing an
Examining the data more closely, researchers found that among
premenopausal women, those who consumed the most isoflavones had a
30 percent decreased risk of early, stage I disease, a 70 percent
decreased risk of having a tumor larger than 2 centimeters, and a
60 percent decreased risk of having stage 2 breast cancer. These
connections were not seen among postmenopausal women, the
"Eating isoflavones seems to be associated mainly with breast cancer characteristics that are more treatable and less severe than other types," said study lead author Anne Weaver, a graduate student at the University at Buffalo and a research apprentice with Roswell Park Cancer Institute in Buffalo. She and the other researchers noted that the findings were not definitive and needed to be confirmed through further research.
"The biggest source of isoflavones are soy and soy products but they're also found in beans, cooked cereal, potato chips, coffee, cookies and cake," Weaver said. She cautioned that the overall intake of soy in the study was low -- in fact, 75 percent of participants reported never eating soy at all.
The hormone replacement therapy study aimed to see if different
types of treatment (estrogen alone or estrogen-plus-progestin), the
form of treatment (pill, patch, cream), or whether or not it was
taken sequentially or continuously affected ovarian cancer
During the 1990s, hormone replacement therapy was widely used by
women to help control menopausal symptoms. However, data from the
Women's Health Initiative study in 2002 suggested that the
treatment raised risks for cardiovascular events and breast cancer,
and rates of use fell precipitously.
In the new study, the authors examined data on almost 127,000
postmenopausal women in 10 European countries.
"Current use of hormone therapy was associated with a small but significant increased risk of ovarian cancer [29 percent compared to women who had never used hormone therapy] but there was no association for former use," said study lead author Konstantinos Tsilidis, a postdoctoral fellow in the Cancer Epidemiology Unit at the University of Oxford.
The longer a woman used the therapy, the higher the risk,
although the only significant risk was seen among women who used
hormone therapy for over five years. There seemed to be no
difference in risk between type of therapy, by regimen or route of
A third study presented at the conference found a heavy burden
of side effects -- including hot flashes, sleep aberrations, hair
loss and leg cramps -- in women taking aromatase inhibitor
medications to treat their breast cancer.
"Aromatase inhibitors are associated with the new onset of a number of symptoms that occur much more frequently in women with breast cancer compared to women of the same age without cancer," said study lead author Lisa Gallicchio, an epidemiologist with the Prevention and Research Center at Mercy Medical Center in Baltimore. "These symptoms may affect quality of life and medication adherence which is crucial in reducing breast cancer recurrence and breast cancer-related mortality."
A previous study found that only 49 percent of patients took
aromatase inhibitors "at the full duration at the optimal
schedule," Gallicchio said. "That means 51 percent did not."
The current research was partially funded by pharmaceutical
company Astra Zeneca.
A final study, this time by researchers at Yale University,
found that exercising for at least 150 minutes a week reduces the
odds of developing endometrial cancer by 34 percent.
The benefit was greater for slim women, who had a 73 percent
reduced risk compared with heavy, sedentary women. But even
overweight and obese women who exercised had a 52 percent reduced
risk compared to their counterparts who didn't exercise.
The U.S. National Cancer Institute has more on
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.